Open AccessManaging QT prolongation in the Era of Coronavirus Disease 2019 (COVID-19)
Author(s) -
Sidhi Laksono,
Dony Yugo Hermanto,
Muhammad Iqbal
Publication year - 2020
Publication title -
majalah kardiologi indonesia
Language(s) - English
Resource type - Journals
eISSN - 2620-4762
pISSN - 0126-3773
DOI - 10.30701/ijc.v1i1.1002
Subject(s) - hydroxychloroquine , medicine , qt interval , azithromycin , covid-19 , chloroquine , outbreak , intensive care medicine , prolongation , coronavirus , disease , sepsis , drug , virology , infectious disease (medical specialty) , pharmacology , antibiotics , immunology , malaria , microbiology and biotechnology , biology
Indonesia has declared a COVID-19 outbreaks because of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in March 2020. COVID-19 has significantly increased morbidity and mortality worldwide. Some studies have shown good clinical outcomes with the use of combination of chloroquine or hydroxychloroquine and azithromycin. That drugs can prolong the QT interval and increase the risk of Torsade de Pointes (TdP). The risk is increasing in several conditions such as in critical patients, metabolic disorders, sepsis, multiorgan dysfunction and with drug-drug interactions. Cardiologists need to know how to manage this condition to reduce the risk of TdP.